The primary efficacy endpoint examines the hypothesis that ABT-436 will decrease the weekly
percentage of heavy drinking days during Study Weeks 2 through 12 (Days 8-84) as compared to
placebo. A "heavy drinking day" is 4 or more drinks per drinking day for women and 5 or more
drinks per drinking day for men.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)